Soros Fund Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Soros Fund Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-4,908	Closed	-$90K	–	388
2014 Q2	$90K	Buy	+4,908	New	+$63.8K	﹤0.01%	328

Other funds holding AVEO

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

DVC

Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Soros Fund Management's AVEO Position: Q3 2014 in Review

Soros Fund Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2014, closing a stake of 4,908 shares — an estimated $90K sold.

Soros Fund Management first reported a position in AVEO in Q2 2014 and held it in 1 quarter. The position peaked at $90K in Q2 2014. 55 funds tracked by Wall St. Rank hold AVEO as of Q3 2014.

Soros Fund Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
Soros Fund Management sold 4,908 AVEO Pharmaceuticals, Inc. shares in Q3 2014, an estimated $90K.
Soros Fund Management first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
Soros Fund Management's AVEO Pharmaceuticals, Inc. position peaked at $90K in Q2 2014.
55 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2014.

Based on Soros Fund Management's 13F filing for Q3 2014, filed 14 Nov 2014.